Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients

Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients - Effects of Olmesartan and Azilsartan on CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015671

Enrollment

Registered

2014-12-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Treat patients with Olmesartan (20mg) for 6 months, and then change it with Azilsartan (20mg) and treat them for additional 6 months. Measure biomarkers on 0, 6, and 12 months. Treat patients with Az

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD stage G3b to G4, and A2 to A3 uncontrolled high blood pressure (>130/80) under treatment with antihypertensives other than ARB

Exclusion criteria

Exclusion criteria: Allergy to ARB Liver dysfunction Pregnancy Inappropriate patients judged by their physiocians

Design outcomes

Primary

Measure	Time frame
Changes in CKD biomarkers such as urinary protein, urinary L-FABP and renal hypoxia measured by BOLD-MRI, and CAVI as an arteriosclerosis biomarker	—

Countries

Japan

Contacts

Public ContactTsutomu Inoue

Saitama Medical University Department of Nephrology

t_inoue@saitama-med.ac.jp049-276-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026